Landos Biopharma, Inc.
(NASDAQ CM: LABP)
Rigrodsky Law, P.A. is investigating Landos Biopharma, Inc. (“Landos”) regarding possible breaches of fiduciary duties and other violations of law related to Landos’s agreement to be acquired by AbbVie Inc. Under the terms of the agreement, Landos shareholders will receive $20.42 per share in cash upon closing, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, subject to the achievement of a clinical development milestone.